Recent improvements in protein-based drug delivery technologies, specifically bovine serum albumin (BSA)-encapsulated nanoparticles, have enhanced the solubility, bioavailability, and targeted cytotoxicity of EVO in BC cells. Here, ALB is linked to breast cancer.